Nifty Pharma Q2 FY27 results: net profit down 19.8%
Key Highlights
Nifty Pharma Q2 FY27 results show a combined net profit of ₹5,839 crore. The combined revenue for the 8 reported companies was ₹48,235 crore.
Updated: Saturday 31 October 2026
- 8 companies of the 20 in the Nifty Pharma index have reported Q2 FY27 results.
- Combined net profit: ₹5,839 crore, 19.81% lower than a year earlier.
- Combined revenue: ₹48,235 crore, 12.31% higher than a year earlier.
- Net profit margin: 12.11% (16.96% a year earlier).
- 12 companies still to report.
Nifty Pharma Q2 FY27 results show that 8 companies have reported a combined net profit of ₹5,839 crore, which is 19.81% lower than a year earlier. These 8 companies recorded a combined revenue of ₹48,235 crore, 12.31% higher than the same quarter a year ago.
Nifty Pharma Q2 FY27 results: the combined numbers
| Q2 FY27 | A year earlier | Change | Companies | |
|---|---|---|---|---|
| from operations | 48,235 | 42,946 | +12.31% | 8 |
| Net profit | 5,839 | 7,282 | −19.81% | 8 |
| Net profit margin | 12.11% | 16.96% | −4.85 pts | 8 |
Combined figures add the companies that reported both the quarter and the same quarter a year earlier, so they compare like with like. A company that has not reported is not in them.
The combined net profit margin for these 8 companies stands at 12.11%, compared to 16.96% a year earlier. Net profit was higher in about half of the companies and lower in about half of the companies, with 8 companies reporting.
Nifty Pharma companies that have reported Q2 FY27
| Company | Revenue from operations | Net profit | Revenue from operations change | Net profit change | Net profit margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical | 16,199 | 1,995 | +11.88% | −36.16% | 12.32% |
| Dr. Reddy’s Laboratories | 8,698 | 913 | −1.48% | −31.69% | 10.50% |
| Cipla | 7,404 | 852 | −2.44% | −37.08% | 11.50% |
| Mankind Pharma | 4,338 | 716 | +17.33% | +37.67% | 16.51% |
| Torrent Pharmaceuticals | 4,979 | 534 | +50.79% | −9.64% | 10.73% |
| Laurus Labs | 2,206 | 436 | +33.44% | +124.27% | 19.77% |
| Ajanta Pharma | 1,794 | 388 | +32.53% | +49.18% | 21.63% |
| Piramal Pharma | 2,617 | 5.0 | +28.05% | – | 0.19% |
Sun Pharmaceutical recorded the largest net profit among the group at ₹1,995 crore. Laurus Labs saw the largest net profit change on a year earlier, with a figure 124.27% higher. Cipla reported a net profit change that was 37.08% lower than the same period last year.
Nifty Pharma companies still to report
| Company | Board meeting |
|---|---|
| Abbott India | 5 Nov 2026 |
| Alkem Laboratories | Date not announced |
| Aurobindo Pharma | 4 Nov 2026 |
| Biocon | 4 Nov 2026 |
| Divi’s Laboratories | 7 Nov 2026 |
| Gland Pharma | 6 Nov 2026 |
| Glenmark Pharmaceuticals | 5 Nov 2026 |
| Ipca Laboratories | 5 Nov 2026 |
| Lupin | 3 Nov 2026 |
| Sai Life Sciences | 5 Nov 2026 |
| Wockhardt | 2 Nov 2026 |
| Zydus Lifesciences | 4 Nov 2026 |
There are 12 companies in the Nifty Pharma index that have yet to report their results. Wockhardt reports on 2026-11-02, while Lupin reports on 2026-11-03, and Aurobindo Pharma reports on 2026-11-04.
Nifty Pharma Q2 FY27 results: FAQs
How did Nifty Pharma companies do in Q2 FY27?
8 companies of the 20 in the Nifty Pharma index have reported Q2 FY27 results. Their combined net profit was ₹5,839 crore, 19.81% lower than a year earlier. Combined revenue was ₹48,235 crore, 12.31% higher than a year earlier. Only companies with both quarters are added.
Which Nifty Pharma company reported the largest net profit in Q2 FY27?
Sun Pharmaceutical, with a net profit of ₹1,995 crore, 36.16% lower than a year earlier.
Which Nifty Pharma companies are yet to report Q2 FY27 results?
Abbott India, Alkem Laboratories, Aurobindo Pharma, Biocon, Divi’s Laboratories, Gland Pharma, Glenmark Pharmaceuticals, Ipca Laboratories and 4 more. The table lists the board-meeting dates the companies have announced.
Results are the companies’ filings to the exchanges; board-meeting dates are from their notices. Calculations are by ThePip. For information only; not investment advice.